Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease

Annals of Internal Medicine

Volumn 137, Issue 4, 2002, Pages 273-284

  Humphrey, Linda L ^a   Chan, Benjamin K S ^a   Sox, Harold C ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE;

ALCOHOL CONSUMPTION; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; CORONARY ARTERY DISEASE; EXERCISE; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; MEDLINE; META ANALYSIS; MORTALITY; POSTMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOCIOECONOMICS;

EID: 0037143553     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-137-4-200208200-00012     Document Type: Review

References (82)

1. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
2. Heart and Estrogen/progestin Replacement Study (HERS): Design, methods, and baseline characteristics
3. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
4. A clinical trial of estrogen-replacement therapy after ischemic stroke
5. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial
6. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause
7. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
8. Current methods of the US Preventive Services Task Force: A review of the process
9. Prior to use of estrogen replacement therapy, are users healthier than nonusers?
10. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study
11. Risk factors for acute myocardial infarction in women: Evidence from the Royal College of General Practitioners' oral contraception study
12. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT)
13. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women
14. A case-control study of myocardial infarction in relation to use of estrogen supplements
15. Biologic and psychosocial risk factors of sudden death from coronary disease in white women
16. Cardiovascular disease and hormone replacement treatment: A pilot case-control study
17. Noncontraceptive estrogens and nonfatal myocardial infarction
18. Risk factors for myocardial infarction in young women
19. Menopausal oestrogen therapy and protection from death from ischaemic heart disease
20. Estrogen use and myocardial infarction risk: A case-control study
21. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women
22. The impact of long term estrogen support after hysterectomy. A report of 1016 cases
23. Cardiovascular disease and non-contraceptive oestrogen therapy
24. Effects of long-term estrogen replacement therapy.I. Metabolic effects
25. Estrogen use and catdiovascular disease
26. Mortality in a cohort of long-term users of hormone replacement therapy: An updated analysis
27. Decreased mortality in users of estrogen replacement therapy
28. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement
29. Postmenopausal estrogen replacement: A long-term cohort study
30. Evidence of a healthy estrogen user survivot effect
31. Reduced mortality associated with long-term postmenopausal estrogen therapy
32. Cause-specific mortality in women receiving hormone replacement therapy
33. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
34. A prospective study of postmenopausal estrogen therapy and coronary heart disease
35. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study
36. Special report: Cardiovascular disease in women. Special writing group
37. Estrogen replacement therapy and mortality among older women. The study of osteoporotic fractures
38. Postmenopausal hormone therapy and mortality
39. Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogeneous community
40. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study
41. Noncontraceptive estrogens and mortality: Long-term follow-up of women in the Walnut Creek Study
42. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: Evidence from a national cohort
43. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women
44. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women
45. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials
46. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease
47. Use of replacement estrogens and the risk of myocardial infarction
48. Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study
49. A study of the association between hormone replacement therapy, smoking and the occurrence of myocardial infarction in women
50. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women
51. Coronary risk and estrogen use in postmenopausal women
52. The Rochester Coronary Heart Disease Project: Effect of cigarette smoking, hypertension, diabetes, and steroidal estrogen use on coronary heart disease among 40- to 59-year-old women, 1960 through 1982
53. Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems
54. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
55. Hormone therapy to prevent disease and prolong life in postmenopausal women
56. Hormone replacement therapy, heart disease, and other considerations
57. Social class and coronary heart disease
58. Postmenopausal estrogen and prevention bias
59. Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: Evidence of confounding by exposure characteristics
60. Prior and current health characteristics of postmenopausal estrogen replacement therapy users compared with nonusers
61. Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy
62. Postmenopausal hormone replacement therapy and stroke: A meta-analysis
63. How much of the cardioprotective effect of postmenopausal estrogens is real?
64. The treatment of unrelated disorders in patients with chronic medical diseases
65. Randomized tfal of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
66. Hormone replacement therapy and heart disease prevention: Experimentation trumps observation
67. Treatment adherence and risk of death after a myocardial infarction
68. The relationship of treatment adherence to the risk of death after myocardial infarction in women
69. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
70. Factor V Leiden mutation and the risks for thromboembolic disease: A clinical perspective
71. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy
72. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women
73. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study
74. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up
75. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy
76. Early risks of hormone therapy in patients with coronary heart disease
77. Postmenopausal estrogen replacement and risk for venous thromboembolism: A systematic review and meta-analysis for the U.S. Preventive Services Task Force
78. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized trial